Fax: (817) 759-7030
Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma†
Version of Record online: 21 SEP 2005
Copyright © 2005 American Cancer Society
Volume 104, Issue 9, pages 1956–1961, 1 November 2005
How to Cite
Page, R. D., Smith, F. P., Geils, G. F., Beall, C. L., Fridman, M. and Allen, B. J. (2005), Dose-dense vinorelbine and docetaxel with Filgrastim support in patients with advanced nonsmall cell lung carcinoma. Cancer, 104: 1956–1961. doi: 10.1002/cncr.21400
Presented at the 40th annual meeting of the American Society of Clinical Oncology, New Orleans, Louisiana, June 5–8, 2004.
- Issue online: 17 OCT 2005
- Version of Record online: 21 SEP 2005
- Manuscript Accepted: 16 MAY 2005
- Manuscript Revised: 25 APR 2005
- Manuscript Received: 2 FEB 2005
- Amgen Inc., Thousand Oaks, CA
- nonsmall cell lung carcinoma;
Vinorelbine and docetaxel are active single agents in the treatment of nonsmall cell lung carcinoma (NSCLC) and may provide enhanced activity when combined in a dose-dense fashion. The efficacy and safety of this combination was assessed when it was administered every 14 days with Filgrastim support in a community practice setting.
This open-label study was conducted at 12 community oncology practices in the United States. Sixty-one chemotherapy-naive patients with Stage IIIB/IV NSCLC received vinorelbine 45 mg/m2 followed by docetaxel 60 mg/m2 on Day 1 and Filgrastim 5 mcg/kg beginning on Day 2, with cycles repeated every 14 days.
Among 61 enrolled patients, 44% of patients had either a complete or partial response as their best response, and 27% of patients had confirmed complete or partial responses. The median time to confirmed response was 1.9 months (95% confidence interval [95% CI], 0.9–2.3 mos), and the median duration of confirmed response was 6.0 months (95% CI, 3.1–14.4 mos). The median time to disease progression was 4.9 months (95% CI, 3.8–5.8 mos). With a median follow-up of 14.3 months, the median survival was 12.9 months (95% CI, 8.1–14.3 mos), and the 1-year survival rate was 56% (95% CI, 43–69%). The relative dose intensity was 94% for vinorelbine and 93% for docetaxel. Febrile neutropenia occurred in 9 patients (15%) and during 9 of 351 cycles (3%).
It was possible to administer dose-dense vinorelbine and docetaxel chemotherapy with Filgrastim support, beginning in the first cycle, to patients with NSCLC who were treated in a community practice setting. Cancer 2005. © 2005 American Cancer Society.